Innovative approaches to stay ahead of regulatory change.
通过现实世界扩展您的选择
Increasingly, regulatory authorities are seeing the value of real world evidence (RWE) to evaluate a product’s safety and effectiveness. This changing environment presents you with new opportunities to increase the effectiveness and efficiency of your safety and regulatory studies.
At IQVIA, our global scientific and operational experts are developing innovative approaches for RWE study design and execution. Leverage secondary and primary data directly from patients and physicians to plan the most efficient study design for your needs. Applications include
- Post-Authorization Safety Studies (PASS)
- Post-Authorization Effectiveness Studies (PAES)
- Drug Utilization Studies (DUS)
- Risk Evaluation and Mitigation Strategy (REMS)
- EU Risk Management Plan
- Pregnancy Registries
- Vaccine Registries
- Expanded Access Programs (EAPs)
- Label Expansion Studies
现实世界的专业知识
To best support your research, IQVIA nurtures extensive scientific affiliations and maintains a strong commitment to research excellence. We are active partners and participants with OMOP, ENCePP, EUnetHTA, IMI, the Department of Health and Human Services, and maintain numerous academic affiliations. We help you meet regulatory needs, using RWE to accelerate approvals and label expansions in the U.S. and EU.
Richer real world data insights can drive smarter decisions.
Use emerging data sources and advances in evidence methods to demonstrate product value and safety.